


EORTC 55994: Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO stage Ib2, IIa > 4 cm or IIb cervical cancer.



PI's: G. Kenter, S. Greggi, F. Landoni



Primary endpoint:

- Overall survival at five years

Secondary endpoints:

- Overall survival
- Progression free survival
- Toxicity
- Quality of life

- **Accrual (n = 626) completed June 2014**
 - Expected study completion = mid 2019
- **Protocol amendment (v4.0):**
 - New primary end-point: OS at 5 years instead of OS
 - Secondary end-point: OS
 - Change of total number of patients: 625 (instead of 686)
 - Revised TR chapter

EORTC 55994: Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO stage Ib2, IIa > 4 cm or IIb cervical

SHORT TERM TOXICITY and PRELIMINARY RESULTS FROM EORTC 55994 COMPARING NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY TO CHEMORADIATION FOR LOCALLY ADVANCED (Stage IB2-IIIB) CERVICAL CANCER

IGCS, Lisbon 2016 (Saturday afternoon)